JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

EGFR, HER2 & Receptor Tyrosine Kinases

Receptor tyrosine kinase antibodies bind growth factor receptors such as epidermal growth factor receptor (EGFR). Cetuximab, panitumumab and necitumumab block ligand binding to EGFR, and amivantamab binds both EGFR and the MET receptor. Trastuzumab, pertuzumab and margetuximab bind distinct epitopes of the HER2 receptor, and patritumab targets HER3 on tumor cells. Teprotumumab binds insulin-like growth factor 1 receptor (IGF-1R), and onartuzumab is a one-armed antibody against MET. Further antibodies target fibroblast growth factor receptors, AXL, EphA2, KIT and protein tyrosine kinase 7 (PTK7).

Cat. No.

AT0688

CAS No.

2517935-02-1

Fazpilodemab

Synonyms: BFKB8488A; RG-7992; RO-7040551

Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody designed to specifically target fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. This antibody is engineered for the investigation of metabolic disorders, particularly type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Fazpilodemab's dual targeting mechanism facilitates the study of signaling pathways that may play critical roles in the pathophysiology of these conditions.

In stock View Details

1 mg

$560.00

5 mg

$1,456.00

All 3 sizes

EGFR, HER2 & Receptor Tyrosine Kinases

Fazpilodemab